Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CDC25A | P30304 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400315 | 0.95 | KDM4E (0.41) | KDM4ELMNAATMKDM1ASLC16A3 | |
| SCHEMBL5580245 | 0.93 | KDM4E (0.40) | KDM4ELMNAATMKDM1ASLC16A3 | |
| SCHEMBL1275063 | 0.93 | KDM4E (0.40) | KDM4ELMNAATMKDM1ASLC16A3 | |
| SCHEMBL1274438 | 0.93 | KDM4E (0.40) | KDM4ELMNAATMKDM1ASLC16A3 | |
| SCHEMBL451000 | 0.89 | KDM4E (0.43) | KDM4ELMNAATMKDM1ASLC16A3 | |
| SCHEMBL116432 | 0.79 | EP300 (0.47) | SLC16A3SLC16A1 | |
| SCHEMBL5037139 | 0.79 | EP300 (0.47) | SLC16A3SLC16A1 | |
| SCHEMBL5935303 | 0.79 | EP300 (0.47) | SLC16A3SLC16A1 | |
| SCHEMBL9361015 | 0.78 | EP300 (0.55) | LMNABLM | |
| SCHEMBL447973 | 0.78 | EP300 (0.55) | LMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 647 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195443-A1 | Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof | ANP TECHNOLOGIES, INC. (US) | 2025-06-19 | — | — | US | claimed |
| US-20250108106-A1 | NANOENCAPSULATED PHARMACEUTICAL COMPOSITION AND USE THEREOF | FULGENT GENETICS, INC. | 2025-04-03 | — | — | US | claimed |
| EP-4493219-A1 | POLYMER NANOAGGREGATE PHARMACEUTICAL COMPOSITION AND USE THEREOF | ANP Technologies, Inc. (US) | 2025-01-22 | — | — | EP | claimed |
| WO-2023177629-A1 | POLYMER NANOAGGREGATE PHARMACEUTICAL COMPOSITION AND USE THEREOF | ANP TECHNOLOGIES, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| WO-2023178038-A1 | NANOENCAPSULATED PHARMACEUTICAL COMPOSITION AND USE THEREOF | FULGENT GENETICS, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| EP-3478822-B1 | PRESERVATION OF MICROORGANISMS | Yun NV (BE) | 2023-06-07 | — | — | EP | claimed |
| CN-109913400-B | Artificial tissue precursors and methods for making same | 四川蓝光英诺生物科技股份有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-20220323368-A1 | ACTIVE SUBSTANCE DELIVERY SYSTEM WITH DELAYED DELIVERY | CAPNOPHARM GMBH (DE) | 2022-10-13 | — | — | US | claimed |
| CN-109735434-B | Artificial tissue precursors and methods of making the same | 四川蓝光英诺生物科技股份有限公司 | 2022-09-23 | — | — | CN | claimed |
| US-20220241213-A1 | DELAYED AND SUSTAINED DELIVERY OF ANTICANCER DRUGS | CAPNOPHARM GMBH (DE) | 2022-08-04 | — | — | US | claimed |
| EP-1427289-A2 | PULSATILE RELEASE COMPOSITIONS AND METHODS FOR ENHANCED GASTROINTESTINAL DRUG ABSORPTION | ISIS Pharmaceuticals, Inc. (US) | 2004-06-16 | — | — | EP | claimed |
| EP-0820300-B1 | CONTROLLED RELEASE BIODEGRADABLE NANOPARTICLES CONTAINING INSULIN | ELAN CORP PLC (IE) | 2004-03-10 | — | — | EP | claimed |
| WO-2004000287-A1 | TARGETING SYSTEM COMPRISING UNIFORMLY-SIZED NANOPARTICLES WITH AT LEAST ONE POLYMER AND AT LEAST ONE POSITIVELY-CHARGED POLYSACCHARIDE AND PREPARATION METHOD THEREOF | BIOALLIANCE PHARMA (FR) | 2003-12-31 | — | — | WO | claimed |
| US-20030124196-A1 | Pulsatile release compositions and methods for enhanced intestinal drug absorption | ISIS PHARMACEUTICALS, INC. | 2003-07-03 | — | — | US | claimed |
| WO-2003017940-A2 | PULSATILE RELEASE COMPOSITIONS AND METHODS FOR ENHANCED GASTROINTESTINAL DRUG ABSORPTION | ISIS PHARMACEUTICALS, INC. (US) | 2003-03-06 | — | — | WO | claimed |
| US-20020065314-A1 | COMPOSITIONS AND METHOD FOR STIMULATING HAIR GROWTH | S.N. BIOTECH, INC. | 2002-05-30 | — | — | US | claimed |
| EP-0820300-A1 | CONTROLLED RELEASE BIODEGRADABLE NANOPARTICLES CONTAINING INSULIN | ELAN CORPORATION PLC (IE) | 1998-01-28 | — | — | EP | claimed |
| US-5641515-A | COMPLEX OF INSULIN AND POLYALKYLCYANOACRYLATE OR FREE-INSULIN LOADED POLYALKYLCYANOACRYLATE | ELAN CORPORATION, PLC (IE) | 1997-06-24 | — | — | US | claimed |
| WO-1996031231-A1 | CONTROLLED RELEASE BIODEGRADABLE NANOPARTICLES CONTAINING INSULIN | ELAN CORPORATION, PLC (IE) | 1996-10-10 | — | — | WO | claimed |
| WO-1996018635-A1 | FULLERENE-OLIGONUCLEOTIDE OR FULLERENE-NUCLEOTIDE CONJUGATES, COMPLEXES THEREOF WITH NANOPARTICLES, AND THERAPEUTICAL USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1996-06-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065314-A1 | COMPOSITIONS AND METHOD FOR STIMULATING HAIR GROWTH | AREG, NGF, HDGF | KDM4E 4496/4885LMNA 3582/4885ATM 4360/4885 |
| US-20250195443-A1 | Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof | BRCA1, TP53, PRNP | KDM4E 4643/4885LMNA 3498/4885ATM 1141/4885 |
| US-20250108106-A1 | NANOENCAPSULATED PHARMACEUTICAL COMPOSITION AND USE THEREOF | STING1, CGAS, MAVS | KDM4E 3843/4885LMNA 1810/4885ATM 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.